A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The ÄKTA explorer was the first high end FPLC (Fast Protein Liquid Chromatography) system that was developed for Life Science research by the Swedish company Pharmacia in 1994. Its purpose was to simplify and automatize protein purification. It was followed by a line of similar devices (the "Äkta" line). The product line name was transferred together with the sale of Pharmacia first to Amersham and then to GE Healthcare. Although protein purification is possible with a large range of chromatographic devices, the Äkta line represents together with BioRad's NGC line the only devices that were specifically designed for this purpose both from the hardware and software perspective. Main users of these devices are the pharmaceutical industry and academic researchers.
== Motorsport and racing scandals == 1994 Formula One cheating controversy – a number of allegations of cheating were thrown during the 1994 Formula One season, particularly to the Benetton team. 2007 NASCAR Gatorade Duel scandal – three various incidents related to the Gatorade Duel. 2007 Formula One espionage controversy, commonly known as Spygate – an incident in which Scuderia Ferrari mechanic Nigel Stepney passed on a secret document to Mike Coughlan of McLaren. 2008 race fixing controversy, also known as Crashgate – it was surrounded by allegations in Formula One that driver Nelson Piquet Jr. deliberately crashed in the 2008 Singapore Grand Prix to help his Renault teammate Fernando Alonso win. Felipe Massa is pursuing legal action against Formula One Management, the FIA and Bernie Ecclestone for a sum of £64m over Crashgate as he believes the FIA should have voided all points awarded in the Singapore Grand Prix, which would have led to him being 2008 World Champion. A High Court of justice in London has ruled that the case can now go to trial. 2013 Federated Auto Parts 400 – in the final Sprint Cup race, before the field was set for the 2013 Chase for the Sprint Cup, three teams—Michael Waltrip Racing, Penske Racing and Front Row Motorsports—were found to have extensively manipulated the race finish in an attempt to secure Chase places for MWR driver Martin Truex Jr. and Penske driver Joey Logano.
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.
Sources: en.wikipedia.org
In maggot debridement therapy, sterile, medical-grade larvae of the necrophagous fly Lucilia sericata are used to eliminate necrotic (dead) tissue from non-healing skin and soft-tissue wounds. This is important as dead tissue can facilitate bacterial growth, impede wound healing, and reduce the effectiveness of topical medications. Physicians may administer the fly larvae directly to skin and soft tissue wounds or indirectly within a sealed mesh bag. Larvae then debride the wound by digesting, liquefying and consuming the dead tissue. The US Food and Drug Administration (FDA) have cleared Lucilia sericata larvae for use as a "medical device" in the US to debride several types of wound including pressure ulcers, neuropathic foot ulcers, and nonhealing surgical wounds.
Motorsport Space travel Sports equipment Sailing Orthopedic technology in orthotics as well as in prosthetics In electrical engineering as an "intermediate layer" in multilayer circuit boards and as insulating material for electrical machines and transformers Rotor blades in wind turbines
Some criminal syndicates have been known to hold their own "trials" for members of theirs who had been accused of wrongdoing; the punishments that the accused member would face if "found guilty" would vary depending on the offense.
Based upon the available area of nasal skin, the surgeon selects the locale for the bilobed flap, and orients the pedicle. If the defect is in the lateral aspect of the nose, the pedicle is based medially. If the defect is at the nasal tip, or at the nasal dorsum, the pedicle is based laterally. An ideal location for the second flap is along the junction of the nasal dorsum and the lateral nasal wall. The nasal wound is cut and shaped into a teardrop form, by the cutting out of a Burrow's triangle of flesh on the side of pedicle base. Cutting out the Burrow's triangle (skin and subcutaneous fat) permits the moving the pedicle flap, to emplace it without buckling the tissues adjacent to the graft. Using a 20 mm calliper as a protractor—one tip at the apex of the wound—the surgeon delineates two semi-circles, an inner semi-circle, and an outer semi-circle. The outer semi-circle defines the necessary length of the two lobes of the skin flap. The inner semi-circle bisects the center of the original wound, and continues across the donor skin, establishing limit measure of the pedicle common to the two lobes of the flap. The surgeon then draws two lines from the apex of the wound; the first line drawn is at an angle of 45 degrees from the long axis of the wound, and the second line drawn is at a 90-degree angle from the axis of the wound. The two lines delineate the central axes of the two lobes of the bilobed flap.
Sources: en.wikipedia.org
== External links == Gen-Z Matters More than Millennials: Goldman Sachs' Christopher Wolf. March 4, 2016. (Video, 3:21) We asked teenagers what adults are missing about technology. This was the best response. Taylor Fang. MIT Technology Review. December 21, 2019. Gen Y vs Z. Zeihan on Geopolitics. December 29, 2021. Why modern America creates fragile children. Jonathan Haidt, April 5, 2023.
The skin and the underlying soft tissues of the alar lobule form a semi-rigid anatomic unit that maintains the graceful curve of the alar rim, and the patency (openness) of the nostrils (anterior nares). To preserve this nasal shape and patency, the replacement of the alar lobule must include a supporting cartilage graft—despite the alar lobule not originally containing cartilage; because of its many sebaceous glands, the nasal skin usually is of a smooth (oiled) texture. Moreover, regarding scarrification, when compared to the skin of other facial areas, the skin of the nose generates fine-line scars that usually are inconspicuous, which allows the surgeon to strategically hide the surgical scars.
== Further reading == Harary, Isaac; Korey, Saul R.; Ochoa, Severo (August 1953). "Biosynthesis of dicarboxylic acids by carbon dioxide fixation. VII. Equilibrium of malic enzyme reaction". The Journal of Biological Chemistry. 203 (2): 595–604. doi:10.1016/S0021-9258(19)52329-8. PMID 13084629. Ochoa S, Mehler AH, Kornberg A (July 1948). "Biosynthesis of dicarboxylic acids by carbon dioxide fixation; isolation and properties of an enzyme from pigeon liver catalyzing the reversible oxidative decarboxylation of 1-malic acid". The Journal of Biological Chemistry. 174 (3): 979–1000. doi:10.1016/S0021-9258(18)57307-5. PMID 18871257. Rutter WJ, Lardy HA (August 1958). "Purification and properties of pigeon liver malic enzyme". The Journal of Biological Chemistry. 233 (2): 374–82. doi:10.1016/S0021-9258(18)64768-4. PMID 13563505. Stickland RG (December 1959). "Some properties of the malic enzyme of pigeon liver. 1. Conversion of malate into pyruvate". The Biochemical Journal. 73 (4): 646–54. doi:10.1042/bj0730646. PMC 1197115. PMID 13834656. Stickland RG (December 1959). "Some properties of the malic enzyme of pigeon liver. 2. Synthesis of malate from pyruvate". The Biochemical Journal. 73 (4): 654–9. doi:10.1042/bj0730654. PMC 1197116. PMID 13834657. Walker DA (February 1960). "Physiological studies on acid metabolism. 7. Malic enzyme from Kalanchoe crenata: effects of carbon dioxide concentration". The Biochemical Journal. 74 (2): 216–23. doi:10.1042/bj0740216. PMC 1204145. PMID 13842495.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.